Contribution: Industrial Research Assistance Program – Contributions to Firms
Solutions de Diagnostic Biomark inc.
$74,900.00
ARP - Development of a Risk Prediction Model for Early Breast Cancer Detection.
FY 2024-25 · 2025-02-24
Summary
This feasibility project is aiming to develop a non-invasive blood test that can detect breast cancer at a very early stage, when treatment is most effective.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Quebec|Québec, Quebec, Canada
Recipient Type
For-profit organization
Business Number
796635662
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2025-02-24 | 2024-25 | $74,900.00 |
| 1 | 2025-02-24 | 2024-25 | $74,900.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 27 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 27 jours.
Agreement End Date
2025-07-31
Agreement Number
1027445
Agreement Start Date
2025-02-24
Agreement Title
ARP - Development of a Risk Prediction Model for Early Breast Cancer Detection.
Agreement Title (French)
PRA - Développement d’un modèle de prédiction des risques pour la détection précoce du cancer du sein.
Agreement Type
Contribution
Agreement Value
$74,900.00
Amendment Date
2025-06-26
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This feasibility project is aiming to develop a non-invasive blood test that can detect breast cancer at a very early stage, when treatment is most effective.
Description (French)
Ce projet de faisabilité vise à développer un test sanguin non invasif capable de détecter le cancer du sein à un stade très précoce, lorsque le traitement est le plus efficace.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Québec
Federal Riding (French)
Québec
Federal Riding Number
24059
NAICS Code
621510
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
796635662
Recipient City
Quebec|Québec
Recipient Country
CA
Recipient Legal Name
Solutions de Diagnostic Biomark inc.
Recipient Operating Name
Biomark Diagnostic Solutions inc.
Recipient Postal Code
G1P 4P5
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2024-2025-Q4-1027445
